Of note, data on Lyn−/−Irf5fl/fl mice meant that the induction therapy alone without Irf5 deletion did not suppress ISG expression; this finding is reminiscent of human SLE patient data in the remission phase (see Fig. 1). The gene discussed is LYN; the disease is systemic lupus erythematosus.